Navigation Links
Glucose 'Tattoo' Could Track Blood Sugar Levels for Diabetics
Date:6/4/2010

Device includes 'carbon nanotubes' injected under skin, say researchers

FRIDAY, June 4 (HealthDay News) -- In the future, people with diabetes may be able to monitor their blood sugar levels using a glucose "tattoo."

This new type of continuous glucose monitor relies on fluorescent nanoparticle ink injected under the skin to detect blood sugar levels with a watch-sized or smaller monitor worn over the skin, according to the researchers at the Massachusetts Institute of Technology (MIT) who are developing the new technology.

The glucose "tattoo" ink would be made from carbon nanotubes that can reflect infrared light back through the skin to the monitor, and this new device has the potential to free people with diabetes from having to do numerous finger pricks each day or to change a continuous glucose monitor device every three to seven days to keep track of their blood sugar levels.

"Carbon nanotubes will fluoresce in infrared light, and we can decorate the tubes so they fluoresce in response to glucose," explained senior researcher Michael Strano, the Charles and Hilda Roddey associate professor of chemical engineering at MIT.

"When you shine a light on the nanotubes, they'll shine light back at a different wavelength to a watch-type diode that could tell how much glucose is around," said Strano.

He said that the actual monitor that's worn over the skin would probably be watch-sized or smaller, depending on the size of the batteries. "If technology keeps shrinking at the current rate, it will probably be smaller than a watch," he said.

Currently, most people with type 1 diabetes have to prick their fingers up to a dozen times a day to assess their blood sugar levels. The newest technology -- continuous glucose monitoring -- involves placing a small glucose sensor that's implanted into the skin, and must be replaced every three to seven days. These devices also must be calibrated daily using a finger stick at least several times a day. The biggest advantage these devices offer is they let someone with diabetes know whether their blood sugar levels are trending up or down.

The reason this is important is that people with type 1 diabetes have to try to maintain as normal blood sugar levels as possible. If blood sugar levels go too low, people with diabetes can go into a coma, and can even die if they don't do something to raise their blood sugar levels. And, if blood sugar levels are too high, many areas in the body, including the eyes, kidneys and the heart, can be damaged.

"Most of the damage diabetes does occurs over short time periods where glucose is spiking and going out of the normal range. If you could intervene and prevent these spikes, you could mitigate many of the effects of this damaging disease," said Strano.

Strano said the researchers are currently trying the nanoparticles in animals, and so don't yet know what side effects or allergic reactions might occur. "We're proceeding in a cautious way," he said.

"Everybody is looking for a painless way to monitor blood sugar, and this technology sounds good, but I have no idea if it's going to work or not. From here to reality will take a lot of steps and research," said Dr. Joel Zonszein, director of the clinical diabetes center at Montefiore Medical Center in New York City.

Plus, he said, there's always the possibility of an adverse reaction to anything placed inside the body. "Our cells don't like foreign bodies. Already, immune cells very carefully try to reject the continuous glucose monitor sensor and fibrose [form scar tissue] around it," he said.

More information

To learn more about the current advances in continuous glucose monitoring, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.



SOURCES: Michael Strano, Ph.D., Charles and Hilda Roddey associate professor of chemical engineering, Massachusetts Institute of Technology, Cambridge, Mass.; Joel Zonszein, M.D., professor, clinical medicine, and director, clinical diabetes center, Montefiore Medical Center and Albert Einstein College of Medicine, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Lack of cellular enzyme triggers switch in glucose processing
2. Newly identified genes influence insulin and glucose regulation
3. Glucose intolerance in pregnancy associated with postpartum cardiovascular risk
4. Blood glucose self-monitoring: No benefit for non-insulin-dependent patients with type 2 diabetes
5. Tattoo Removal Laser Clinic Announces New PhotoAcoustic Laser Technology
6. Road mapping could be key to curing TB
7. What if You Could Help to Influence the NYC Taxi of Tomorrow?
8. Stronger Ozone Standard Could Dramatically Reduce Asthma, Premature Deaths
9. Mechanical forces could affect gene expression
10. Anger Could Ruin Your Relationship
11. New research on type 2 diabetes could benefit young adults with the condition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: